VolitionRx To Highlight NETs Plasma Biomarker In Precision Medicine At EHSF Malta Conference
Benzinga Newsdesk 9 months ago
News
Showing New Indication for Nu.Q® NETs HENDERSON, Nev., Feb. 4, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the sponsorship of a
Showing New Indication for Nu.Q® NETs
HENDERSON, Nev., Feb. 4, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the sponsorship of a symposium at the European Hidradenitis Suppurativa Foundation (EHSF) Conference in Malta on 5th February.
The session entitled "Empowering Precision‑medicine approach through NETs Plasma Biomarker‑driven personalized treatment" will be presented by Professor Evangelos J. Giamarellos-Bourboulis, M.D., PhD, at the 4th Department of Internal Medicine, ATTIKON University General Hospital, Athens, Greece.